Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform

Molecules. 2023 Jan 14;28(2):841. doi: 10.3390/molecules28020841.

Abstract

The blood-brain barrier (BBB) serves as a protective barrier for the central nervous system (CNS) against drugs that enter the bloodstream. The BBB is a key clinical barrier in the treatment of CNS illnesses because it restricts drug entry into the brain. To bypass this barrier and release relevant drugs into the brain matrix, nanotechnology-based delivery systems have been developed. Given the unstable nature of NPs, an appropriate amount of a biocompatible polymer coating on NPs is thought to have a key role in reducing cellular cytotoxicity while also boosting stability. Human serum albumin (HSA), poly (lactic-co-glycolic acid) (PLGA), Polylactide (PLA), poly (alkyl cyanoacrylate) (PACA), gelatin, and chitosan are only a few of the significant polymers mentioned. In this review article, we categorized polymer-coated nanoparticles from basic to complex drug delivery systems and discussed their application as novel drug carriers to the brain.

Keywords: blood–brain barrier; central nervous system; drug delivery systems; nanotechnology; polymer-coated nanoparticles.

Publication types

  • Review

MeSH terms

  • Blood-Brain Barrier
  • Brain Neoplasms* / drug therapy
  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Lactic Acid
  • Nanoparticles*
  • Neurodegenerative Diseases*
  • Polyglycolic Acid
  • Polylactic Acid-Polyglycolic Acid Copolymer

Substances

  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Drug Carriers

Grants and funding

This research received no external funding.